MAPT and supranuclear palsy, progressive, 1: Despite these limitations, we did observe both an increase in the total mouse tau pathology in neurons treated with PSPT40P1 compared to the seeds control (Fig. 6g and h) and perinuclear pathology characteristic of PSP-induced morphology (Fig. 6g and i).